Cargando…

Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas

Head and neck squamous cell carcinomas (HNSCC) induced by human papillomavirus (HPV) have increased recently in the US. However, the distinct alterations of molecules involved in the death pathways and drug effects targeting inhibitor of apoptosis proteins (IAPs) have not been extensively characteri...

Descripción completa

Detalles Bibliográficos
Autores principales:	An, Yi, Jeon, Jun, Sun, Lillian, Derakhshan, Adeeb, Chen, Jianhong, Carlson, Sophie, Cheng, Hui, Silvin, Christopher, Yang, Xinping, Van Waes, Carter, Chen, Zhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973748/ https://www.ncbi.nlm.nih.gov/pubmed/33737574 http://dx.doi.org/10.1038/s41598-021-85589-5

Ejemplares similares

CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants
por: Trebing, J, et al.
Publicado: (2014)

Restoring TRAILR2/DR5-Mediated Activation of Apoptosis upon Endoplasmic Reticulum Stress as a Therapeutic Strategy in Cancer
por: Mora-Molina, Rocío, et al.
Publicado: (2022)

Editorial: TNFRSF agonists: mode of action and therapeutic opportunities
por: Obermajer, Nataša, et al.
Publicado: (2023)

Stress-induced TRAILR2 expression overcomes TRAIL resistance in cancer cell spheroids
por: Stöhr, Daniela, et al.
Publicado: (2020)

Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells
por: Zhu, Xu, et al.
Publicado: (2018)

Targeting triple-negative breast cancers with the Smac-mimetic birinapant
por: Lalaoui, Najoua, et al.
Publicado: (2020)

Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells
por: Niu, Jin, et al.
Publicado: (2020)

The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo
por: Zhou, Liang, et al.
Publicado: (2019)

Combinatorial Treatment of Birinapant and Zosuquidar Enhances Effective Control of HBV Replication In Vivo
por: Morrish, Emma, et al.
Publicado: (2020)

Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant
por: Fichtner, Michael, et al.
Publicado: (2020)

Efficacy of birinapant in combination with carboplatin in targeting platinum-resistant epithelial ovarian cancers
por: Singh, Tanya, et al.
Publicado: (2022)

Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations
por: Colombo, Marika, et al.
Publicado: (2020)

Role of TRAILR1 and TNFR1A polymorphisms in the susceptibility and pharmacogenetics of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab
por: Morales-Lara, M J, et al.
Publicado: (2010)

Hetero-oligomerization between the TNF receptor superfamily members CD40, Fas and TRAILR2 modulate CD40 signalling
por: Smulski, Cristian R, et al.
Publicado: (2017)

NCTD promotes Birinapant-mediated anticancer activity in breast cancer cells by downregulation of c-FLIP
por: Zhao, Li, et al.
Publicado: (2017)

cIAP1/2 are involved in the radiosensitizing effect of birinapant on NSCLC cell line in vitro
por: Sun, Hao, et al.
Publicado: (2021)

PARP13 regulates cellular mRNA post-transcriptionally and functions as a pro-apoptotic factor by destabilizing TRAILR4 transcript
por: Todorova, Tanya, et al.
Publicado: (2014)

RETRACTED ARTICLE: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
por: La, V., et al.
Publicado: (2017)

Retraction Note: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
por: La, V., et al.
Publicado: (2021)

The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity
por: Song, Edward Z., et al.
Publicado: (2022)

TNFRSF receptor-specific antibody fusion proteins with targeting controlled FcγR-independent agonistic activity
por: Medler, Juliane, et al.
Publicado: (2019)

TGF-β and NF-κB signal pathway cross-talk is mediated through TAK1 and SMAD7 in a subset of head and neck cancers
por: Freudlsperger, Christian, et al.
Publicado: (2012)

Genomics and advances towards precision medicine for head and neck squamous cell carcinoma
por: Van Waes, Carter, et al.
Publicado: (2017)

Systems biology-defined NF-κB regulons, interacting signal pathways and networks are implicated in the malignant phenotype of head and neck cancer cell lines differing in p53 status
por: Yan, Bin, et al.
Publicado: (2008)

TNFα Causes a Shift in Gene Expression of TNFRSF1A and TNFRSF1B Isoforms
por: Perik-Zavodskaia, Olga, et al.
Publicado: (2023)

Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant
por: Zakaria, Z, et al.
Publicado: (2016)

Editorial Expression of Concern: birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
por: La, V., et al.
Publicado: (2018)

Multi‐Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells
por: Zhu, Xu, et al.
Publicado: (2018)

CK2 Phosphorylates and Inhibits TAp73 Tumor Suppressor Function to Promote Expression of Cancer Stem Cell Genes and Phenotype in Head and Neck Cancer()()
por: Lu, Hai, et al.
Publicado: (2014)

Genome-wide identification of novel expression signatures reveal distinct patterns and prevalence of binding motifs for p53, nuclear factor-κB and other signal transcription factors in head and neck squamous cell carcinoma
por: Yan, Bin, et al.
Publicado: (2007)

Unraveling Regulatory Programs for NF-kappaB, p53 and MicroRNAs in Head and Neck Squamous Cell Carcinoma
por: Yan, Bin, et al.
Publicado: (2013)

Regulation of NFκB Signalling by Ubiquitination: A Potential Therapeutic Target in Head and Neck Squamous Cell Carcinoma?
por: Morgan, Ethan L., et al.
Publicado: (2020)

SMAC mimetic birinapant inhibits hepatocellular carcinoma growth by activating the cIAP1/TRAF3 signaling pathway
por: Ding, Jun, et al.
Publicado: (2020)

Examining the In Vitro Efficacy of the IAP Antagonist Birinapant as a Single Agent or in Combination With Dacarbazine to Induce Melanoma Cell Death
por: Vetma, Vesna, et al.
Publicado: (2017)

Association of TNF-α, TNFRSF1A and TNFRSF1B Gene Polymorphisms with the Risk of Sporadic Breast Cancer in Northeast Chinese Han Women
por: Xu, Fengyan, et al.
Publicado: (2014)

Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches
por: Allen, Clint T., et al.
Publicado: (2015)

TNFRSF13B is a potential contributor to prostate cancer
por: Li, Chia-Yang, et al.
Publicado: (2022)

On the TRAIL of Better Therapies: Understanding TNFRSF Structure-Function
por: Vanamee, Éva S., et al.
Publicado: (2020)

The role of TNFRSF11B in development of osteoarthritic cartilage
por: Rodríguez Ruiz, Alejandro, et al.
Publicado: (2021)

Abstract: Characterizing Fat in the Superficial and Intermediate Layers of the Neck: Analyzing Variations with Age using Volumetric Computed Tomography
por: Orra, Susan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2sfjcfcs73h8o8ohfqgkek3qgq